SAN DIEGO - TriLink BioTechnologies, a subsidiary of Maravai LifeSciences (NASDAQ: MRVI), has entered into a License and Supply Agreement with Lonza, a key player in the development and manufacturing sector for the pharma, biotech, and nutrition industries.
The agreement, announced today, allows Lonza to utilize TriLink's proprietary CleanCap® mRNA capping technology for the development of mRNA therapeutics.
The CleanCap® technology, which boasts over 95% capping efficiency, is expected to streamline mRNA production processes, a significant advancement over traditional capping methods. This technology is particularly vital as the use of mRNA as a therapeutic modality is on the rise, with TriLink's CleanCap® capping technology being a part of the majority of approved mRNA and saRNA vaccines since its inception.
Under the terms of the agreement, TriLink will supply Lonza with various CleanCap® cap analogs, including the recently introduced CleanCap® M6, which has shown to increase mRNA expression by over 30% compared to enzymatic capping methods.
These cap analogs will be used in Lonza's global mRNA development and manufacturing services, which span from pre-clinical stages through Phase III programs.
Drew Burch, President of Nucleic Acid Production at TriLink, expressed enthusiasm about the collaboration, highlighting the potential of CleanCap® technology to accelerate programs from discovery to clinical stages.
TriLink BioTechnologies, known for its expertise in nucleic acid and mRNA solutions, provides high-quality materials and services to pharmaceutical and biotech companies. Its CleanCap® mRNA capping technology is one of its patented solutions that has been instrumental in the rapid development and distribution of the COVID-19 vaccine and is also used in treatments for various diseases including oncology, infectious diseases, and neurological disorders.
Maravai LifeSciences, TriLink's parent company, is recognized for its contribution to the life sciences industry by supplying essential products for drug therapies, diagnostics, and vaccine development.
This agreement is based on a press release statement and aims to further the development of critical mRNA therapeutics through the enhanced accessibility of advanced capping technologies.
InvestingPro Insights
In light of TriLink BioTechnologies' new agreement with Lonza, it's pertinent to examine the financial health and market position of Maravai LifeSciences (NASDAQ: MRVI), TriLink's parent company. According to the latest data from InvestingPro, Maravai LifeSciences holds a market capitalization of approximately $1.98 billion, signaling a robust presence in the life sciences industry. Despite a challenging market, the company has demonstrated a strong return over the last three months, with a 35.34% price total return, which may reflect investor confidence in its growth trajectory and recent business developments.
InvestingPro Tips indicate that Maravai LifeSciences has liquid assets that exceed its short-term obligations, suggesting a solid financial footing that could support its operational and strategic initiatives, such as the recent licensing agreement. However, analysts have revised their earnings downwards for the upcoming period and do not anticipate the company will be profitable this year. Additionally, Maravai LifeSciences is trading at a high EBITDA valuation multiple, with an EBITDA of $15.89 million for the last twelve months as of Q4 2023.
For investors seeking more in-depth analysis, there are additional InvestingPro Tips available for Maravai LifeSciences, which can be accessed through the dedicated platform. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes comprehensive financial metrics and expert insights to inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.